Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2010

View Archived Issues

Phase I data support efficacy and safety of MGN-1703 in metastatic tumors

ICOVIR-7 is safe and active in refractory solid tumors

Modified-release prednisone at bedtime improves asthma control

WYE-103231 shows potent activity in thermoregulation and pain

Low mGluR5 binding/expression involved in pathophysiology of MDD

CRHR1 SNPs involved in anxiety improvement in GAD and MDD

Fluvastatin does not influence inflammation markers after stroke

Boehringer Ingelheim claims new FADK1 inhibitors

Lundbeck discovers new NPY Y5 receptor ligands

Bayer Schering Pharma claims new HIF-1 inhibitors

Roche claims new prostanoid DP2 receptor antagonists/partial agonists

Novo Nordisk to soon launch Victoza in Japan

Centocor Ortho Biotech acquires RespiVert

NICE releases initial decision on omalizumab use in children with asthma

FDA approves Prolia therapy for postmenopausal women with osteoporosis

Belgian FAMHP clears phase III Reolysin trial in head and neck cancers

Enrollment begins in phase III rifamycin trial in travelers' diarrhea

NanoViricides' antidengue agents demonstrate preclinical efficacy

FDA grants orphan drug status to THPB in Niemann Pick type C disease

FDA accepts Orexigen's Contrave NDA in obesity for filing

LLS and Onconova partner to develop ESTYBON in high-risk MDS

Final data reported of halted phase III idronoxil trial in ovarian cancer

Dosing complete in phase I trial of ND-0611 for Parkinson's disease

Lorus files IND for phase I trial of anticancer agent LOR-253

Sunesis receives scientific advice from EMA on voreloxin program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...